|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Beta
Amyloid Immunotherapies
Beta amyloid immunotherapy pioneered by our scientists involves
the potential treatment of Alzheimer’s disease by inducing
or enhancing the body’s immune response in order to clear
toxic species of beta amyloid from the brain. In almost a decade
of collaboration with Wyeth, our scientists have been developing
a series of therapeutic monoclonal antibodies (mABs) and active
vaccination approaches that may have the ability to reduce or
clear beta amyloid from the brain. These new approaches have the
potential to alter the underlying cause of the disease by
reducing a key pathway associated with it.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Beta
Amyloid Immunotherapies
Beta amyloid immunotherapy pioneered by Elan involves the
treatment of Alzheimer’s disease by inducing or enhancing
the body’s immune response in order to clear toxic species
of beta amyloid from the brain. In collaboration with Wyeth, our
scientists have been developing a series of monoclonal
antibodies and active immunization approaches that may have the
ability to selectively clear a variety of beta amyloid species.
These new approaches have the potential to deliver
immunotherapies with robust and specific therapeutic activity.
The first candidate from the collaboration with Wyeth, AN-1792
(an immunoconjugate vaccine), showed great promise but was
discontinued in 2002 when a small subset of patients (6%)
developed a type of brain inflammation. The AN-1792 program
played a major role in advancing the understanding of the
relationship between beta amyloid and Alzheimer’s disease,
and contributed to a growing body of scientific evidence
pointing to the promise of immunotherapies as potential
treatments for Alzheimer’s disease. Long-term
follow-up
data presented in 2007 evaluated participants from the AN-1792
Phase 2 clinical trial and found that 4.5 years after
dosing had stopped, patients who had responded to treatment
continued to show significantly slower decline, compared to
placebo patients, on two key measures of patient function: the
Disability Assessment for Dementia and the Dependence Scale.
Based upon the proof of principle established by work on
AN-1792, four distinct new programs emerged that seek to build
upon the promising efficacy signal, including bapineuzumab
(AAB-001), which is generally viewed as one of the most advanced
programs with disease-modifying potential in the field, and
ACC-001.
| EXCERPTS ON THIS PAGE:
|
| |||||||
